Prestwick Pharmaceuticals, Inc, is a product-based, specialty pharmaceutical company engaged in the development and marketing of small molecule drugs for chronic diseases of the central nervous system (CNS).

Following our founding in 2002, we rapidly acquired rights to a promising portfolio of small molecule drugs, all with unique attributes and targeting chronic CNS conditions not adequately served by current therapies. Our portfolio now consists of several product candidates being studied for a range of CNS conditions, including Huntington’s Disease, Parkinson’s disease, restless legs syndrome, schizophrenia, autism, Alzheimer’s disease, and sleep apnea.

We filed our first New Drug Application (NDA) with the U.S. Food and Drug Administration in 2005 for our lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor that is under evaluation in the U.S. for potential use as a treatment for chorea associated with Huntington’s Disease.

We are currently in the process of building a commercial organization to market and sell tetrabenazine in the U.S. upon regulatory approval. Cambridge Laboratories (Ireland), Limited, our licensor for tetrabenazine, has granted us exclusive rights to market and sell tetrabenazine in the U.S. and Canada. We have already established commercial operations in Canada to market and sell tetrabenazine.

We are based in Washington, DC, and are privately held. In addition to a seasoned management team, we have a board of directors that includes senior executives from prominent venture capital firms, biopharmaceutical companies, and civic organizations.

We are committed to becoming a leading specialty pharmaceutical company serving the CNS market.